Stock recommendation on SIGA Technologies affected by mpox outbreak response, diversifying into mAbs for orthopoxviruses, remains speculative buy.

Researchers suggest broadly reactive antibodies identified are likely to represent a common mechanism of acquired immunity to ...

Monoclonal antibodies (mAbs) have been a key therapeutic option for non-communicable diseases for decades, and a small number of mAbs have helped treat infectious diseases, including COVID-19.

Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable TherapeuticsJUPITER, Fla., Nov. 21, ...

A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a ...

Casirivimab and imdevimab in combination is safe among pediatric outpatients with at least 1 risk factor for severe COVID-19.

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

Japanese drugmaker Chugai, which is majority owned by Roche, On Friday revealed that Zenyaku Kogyo has obtained regulatory ...

Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...